277 related articles for article (PubMed ID: 11431335)
1. Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition?
Yang S; Lin HZ; Hwang J; Chacko VP; Diehl AM
Cancer Res; 2001 Jul; 61(13):5016-23. PubMed ID: 11431335
[TBL] [Abstract][Full Text] [Related]
2. Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.
Hookman P; Barkin JS
Am J Gastroenterol; 2003 Sep; 98(9):2093-7. PubMed ID: 14499793
[TBL] [Abstract][Full Text] [Related]
3. Alcohol increases tumor necrosis factor alpha and decreases nuclear factor-kappab to activate hepatic apoptosis in genetically obese mice.
Robin MA; Demeilliers C; Sutton A; Paradis V; Maisonneuve C; Dubois S; Poirel O; Lettéron P; Pessayre D; Fromenty B
Hepatology; 2005 Dec; 42(6):1280-90. PubMed ID: 16317704
[TBL] [Abstract][Full Text] [Related]
4. A novel aminosterol reverses diabetes and fatty liver disease in obese mice.
Takahashi N; Qi Y; Patel HR; Ahima RS
J Hepatol; 2004 Sep; 41(3):391-8. PubMed ID: 15336441
[TBL] [Abstract][Full Text] [Related]
5. Norepinephrine regulates hepatic innate immune system in leptin-deficient mice with nonalcoholic steatohepatitis.
Li Z; Oben JA; Yang S; Lin H; Stafford EA; Soloski MJ; Thomas SA; Diehl AM
Hepatology; 2004 Aug; 40(2):434-41. PubMed ID: 15368448
[TBL] [Abstract][Full Text] [Related]
6. Serum ornithine carbamyltransferase reflects hepatic damage in diabetic obese mice.
Murayama H; Ikemoto M; Hamaoki M
J Gastroenterol Hepatol; 2010 Feb; 25(2):413-9. PubMed ID: 19793175
[TBL] [Abstract][Full Text] [Related]
7. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice.
Dentin R; Benhamed F; Hainault I; Fauveau V; Foufelle F; Dyck JR; Girard J; Postic C
Diabetes; 2006 Aug; 55(8):2159-70. PubMed ID: 16873678
[TBL] [Abstract][Full Text] [Related]
8. Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease.
Yang S; Koteish A; Lin H; Huang J; Roskams T; Dawson V; Diehl AM
Hepatology; 2004 Feb; 39(2):403-11. PubMed ID: 14767993
[TBL] [Abstract][Full Text] [Related]
9. Partial leptin deficiency favors diet-induced obesity and related metabolic disorders in mice.
Begriche K; Lettéron P; Abbey-Toby A; Vadrot N; Robin MA; Bado A; Pessayre D; Fromenty B
Am J Physiol Endocrinol Metab; 2008 May; 294(5):E939-51. PubMed ID: 18349116
[TBL] [Abstract][Full Text] [Related]
10. Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease.
Li Z; Soloski MJ; Diehl AM
Hepatology; 2005 Oct; 42(4):880-5. PubMed ID: 16175608
[TBL] [Abstract][Full Text] [Related]
11. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis.
Brun P; Castagliuolo I; Di Leo V; Buda A; Pinzani M; Palù G; Martines D
Am J Physiol Gastrointest Liver Physiol; 2007 Feb; 292(2):G518-25. PubMed ID: 17023554
[TBL] [Abstract][Full Text] [Related]
12. Obesity-induced lymphocyte hyperresponsiveness to chemokines: a new mechanism of Fatty liver inflammation in obese mice.
Bigorgne AE; Bouchet-Delbos L; Naveau S; Dagher I; Prévot S; Durand-Gasselin I; Couderc J; Valet P; Emilie D; Perlemuter G
Gastroenterology; 2008 May; 134(5):1459-69. PubMed ID: 18471520
[TBL] [Abstract][Full Text] [Related]
13. Mouse livers with macrosteatosis are more susceptible to normothermic ischemic injury than those with microsteatosis.
Selzner N; Selzner M; Jochum W; Amann-Vesti B; Graf R; Clavien PA
J Hepatol; 2006 Apr; 44(4):694-701. PubMed ID: 16229921
[TBL] [Abstract][Full Text] [Related]
14. Enzyme activities of hepatic glucose utilization in the fed and fasting genetically obese mouse at 4-5 months of age.
Hron WT; Sobocinski KA; Menahan LA
Horm Metab Res; 1984 Dec; 16 Suppl 1():32-6. PubMed ID: 6241916
[TBL] [Abstract][Full Text] [Related]
15. Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage.
Guebre-Xabier M; Yang S; Lin HZ; Schwenk R; Krzych U; Diehl AM
Hepatology; 2000 Mar; 31(3):633-40. PubMed ID: 10706553
[TBL] [Abstract][Full Text] [Related]
16. Risk factors associated with nonalcoholic fatty liver disease and its relationship with the hepatic histological changes.
Rodríguez-Hernández H; Gonzalez JL; Márquez-Ramirez MD; Flores-Hernandez M; Rodríguez-Morán M; Guerrero-Romero F
Eur J Gastroenterol Hepatol; 2008 May; 20(5):399-403. PubMed ID: 18403941
[TBL] [Abstract][Full Text] [Related]
17. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation.
Alessi MC; Bastelica D; Mavri A; Morange P; Berthet B; Grino M; Juhan-Vague I
Arterioscler Thromb Vasc Biol; 2003 Jul; 23(7):1262-8. PubMed ID: 12750120
[TBL] [Abstract][Full Text] [Related]
18. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression.
Sekiya M; Yahagi N; Matsuzaka T; Najima Y; Nakakuki M; Nagai R; Ishibashi S; Osuga J; Yamada N; Shimano H
Hepatology; 2003 Dec; 38(6):1529-39. PubMed ID: 14647064
[TBL] [Abstract][Full Text] [Related]
19. iPLA2β deficiency attenuates obesity and hepatic steatosis in ob/ob mice through hepatic fatty-acyl phospholipid remodeling.
Deng X; Wang J; Jiao L; Utaipan T; Tuma-Kellner S; Schmitz G; Liebisch G; Stremmel W; Chamulitrat W
Biochim Biophys Acta; 2016 May; 1861(5):449-61. PubMed ID: 26873633
[TBL] [Abstract][Full Text] [Related]
20. Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines.
Diehl AM
Am J Physiol Gastrointest Liver Physiol; 2002 Jan; 282(1):G1-5. PubMed ID: 11751151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
